Olema Pharmaceuticals, Inc. Contracts & Agreements
43 Contracts & Agreements
- Business Finance (16 contracts)
- Business Operations (8)
- Human Resources (10)
- Uncategorized (9)
- Form of Exchange Warrant (Filed With SEC on January 10, 2025)
- Form of Pre-Funded and Exchange Warrant (Filed With SEC on December 2, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on December 2, 2024)
- First Amendment to Loan and Security Agreement by and between the Registrant and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company, dated June 28, 2024 (Filed With SEC on August 6, 2024)
- Olema Pharmaceuticals, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 6, 2024)
- Amendment No. 2 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated March... (Filed With SEC on May 8, 2024)
- OLEMA PHARMACEUTICALS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on March 11, 2024)
- Sales Agreement by and between Registrant and Cowen and Company, LLC, dated January 5, 2024 (Filed With SEC on January 5, 2024)
- Amendment No. 1 to Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Company and Novartis Institutes for BioMedical Research, Inc., dated... (Filed With SEC on October 10, 2023)
- Stock Purchase Agreement, dated September 5, 2023, by and among the Company and the Purchasers named therein (Filed With SEC on September 5, 2023)
- Loan and Security Agreement, dated September 5, 2023, by and between the Company and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (Filed With SEC on September 5, 2023)
- Amended and Restated Clinical Collaboration and Supply Agreement, by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated January 13, 2022 (Filed With SEC on May 9, 2023)
- Separation Agreement by and between the Registrant and Cyrus Harmon, dated March 21, 2023 (Filed With SEC on May 9, 2023)
- Separation Agreement by and between the Registrant and Kinney Horn, dated March 8, 2023 (Filed With SEC on May 9, 2023)
- Sales Agreement by and between Registrant and Oppenheimer & Co. Inc., dated March 9, 2023 (Filed With SEC on March 9, 2023)
- Drug Discovery Collaboration and License Agreement by and between the Registrant and Aurigene Discovery Technologies Limited, dated June 7, 2022 (Filed With SEC on August 9, 2022)
- Olema Pharmaceuticals, Inc. 2022 Inducement Plan (Filed With SEC on February 28, 2022)
- Form of Stock Option Agreement and Option Grant Notice under the Inducement Plan (Filed With SEC on February 28, 2022)
- Offer Letter by and between the Registrant and Naseem Zojwalla, dated December 15, 2021 (Filed With SEC on February 28, 2022)
- Consulting Agreement by and between the Company and Frank McCormick Ph.D., F.R.S., D.Sc. (Hon), dated April 5, 2021 (Filed With SEC on May 11, 2021)
- Description of Capital Stock (Filed With SEC on March 17, 2021)
- Form of Underwriting Agreement (Filed With SEC on November 16, 2020)
- Form of Common Stock Certificate (Filed With SEC on November 16, 2020)
- Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (Filed With SEC on November 16, 2020)
- Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on November 16, 2020)
- Olema Pharmaceuticals, Inc. 2020 Non-Employee Director Compensation Policy (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and Sean Bohen, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and Cyrus L. Harmon, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and Kinney Horn, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and Shane Kovacs, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and Peter Kushner, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and David Myles, dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Offer Letter by and between the Registrant and John B. Moriarty, Jr., dated November 13, 2020 (Filed With SEC on November 16, 2020)
- Amended and Restated Investors Rights Agreement, by and among the Registrant and certain of its stockholders, dated September 30, 2020 (Filed With SEC on October 30, 2020)
- Olema Pharmaceuticals, Inc. 2014 Stock Plan, as amended (Filed With SEC on October 30, 2020)
- Forms of Stock Option Grant Notice, Stock Option Agreement, Early Exercise Stock Purchase Agreement and Notice of Exercise and Restricted Stock Award Grant Notice and Restricted... (Filed With SEC on October 30, 2020)
- Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (Filed With SEC on October 30, 2020)
- Forms of Stock Option Grant Notice and Stock Option Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (Filed With SEC on October 30, 2020)
- Forms of Restricted Stock Unit Grant Notice and Award Agreement under the Olema Pharmaceuticals, Inc. 2020 Equity Incentive Plan (Filed With SEC on October 30, 2020)
- Olema Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on October 30, 2020)
- Olema Pharmaceuticals, Inc. 2020 Non-Employee Director Compensation Policy (Filed With SEC on October 30, 2020)
- Form of Indemnification Agreement by and between the Registrant and its directors and executive officers (Filed With SEC on October 30, 2020)
- Clinical Collaboration and Supply Agreement by and between the Registrant and Novartis Institutes for BioMedical Research, Inc., dated July 22, 2020 (Filed With SEC on October 30, 2020)
